Jaguar Health Files 10-Q, Details Financial Agreements
Ticker: JAGX · Form: 10-Q · Filed: May 15, 2025 · CIK: 1585608
| Field | Detail |
|---|---|
| Company | Jaguar Health, INC. (JAGX) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financial-agreements, convertible-notes, equity
TL;DR
Jaguar Health 10-Q filed. Shows ongoing deals with Streeterville Capital. Watch for financial updates.
AI Summary
Jaguar Health, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details various financial instruments and agreements, including convertible notes payable and common stock transactions. Notably, it references a March 2021 Purchase Agreement and an August 2022 Purchase Agreement with Streeterville Capital, LLC, indicating ongoing financial arrangements.
Why It Matters
This filing provides insight into Jaguar Health's financial structure and ongoing commitments, which can impact investor confidence and future strategic decisions.
Risk Assessment
Risk Level: medium — The filing involves complex financial instruments and agreements, suggesting potential financial risks and uncertainties for the company.
Key Numbers
- 0.0167 — Five Year (Likely a financial metric or ratio, context unclear without more data)
- 0.04 — Five Year (Likely a financial metric or ratio, context unclear without more data)
Key Players & Entities
- Jaguar Health, Inc. (company) — Filer of the 10-Q
- March 2021 Purchase Agreement (agreement) — Financial agreement referenced
- August 2022 Purchase Agreement (agreement) — Financial agreement referenced
- Streeterville Capital, LLC (company) — Party to purchase agreements
- 2025-03-31 (date) — End of reporting period
FAQ
What is the nature of the "Iliad Royalty Interest" mentioned in relation to fair value measurements?
The filing references "jagx:IliadRoyaltyInterestMember" in the context of "us-gaap:FairValueInputsLevel3Member" and "us-gaap:FairValueMeasurementsRecurringMember" for dates including 2023-12-31 and 2024-12-31, indicating it's an asset valued using Level 3 inputs.
What was the purpose of the "Securities Purchase Agreement" related to convertible notes payable?
The filing mentions "jagx:SecuritiesPurchaseAgreementMember" in conjunction with "us-gaap:ConvertibleNotesPayableMember" for the period ending 2025-03-31, suggesting a transaction involving the issuance or modification of convertible debt.
What are the terms of the "March 2021 Purchase Agreement" and "August 2022 Purchase Agreement" with Streeterville Capital, LLC?
The filing notes these agreements in relation to "jagx:StreetervilleCapitalLlcMember" and specific dates (2025-03-31, 2024-01-01 to 2024-03-31, 2022-08-24), implying ongoing financial arrangements or commitments.
What is the significance of "jagx:CommonStockVotingMember" and "jagx:CommonStockMember" in the context of the filing?
These members are associated with "us-gaap:CommonStockMember" and appear in relation to purchase agreements and dates like 2025-03-31, suggesting transactions involving common stock, potentially as part of financing or equity issuances.
What is the "Equity Incentive Plan 2013" and how are stock options accounted for?
The filing references "jagx:EquityIncentivePlan2013Member" and "jagx:EmployeeAndNonemployeeStockOptionMember" for periods including 2013-11-01 to 2013-11-30 and 2023-01-01 to 2023-12-31, indicating the company's long-term incentive plans for employees and non-employees.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Jaguar Health, Inc. (JAGX).